| 06/01/06 | Imagenetix Announces Positive Safety Studies on Anti-Inflammatory Compound, 1-TDC 1-tetradecanol complex (1-TDC) has achieved expected results in important baseline acute toxicity studies... |
| 05/08/06 | Imagenetix Announces 1-Tetradecanol Complex Acts to Inhibit Bacteria and Enzymes Associated with Oral Disease, Sepsis and Inflammation
1-TDC significantly inhibited the growth of Actinomyces viscosus, a microbe that has been shown to play a major role in oral microbial ecosystems... |
| 04/17/06 | Imagenetix Commences China Sales of New Patented Weight Loss Product
Imagenetix announced it has introduced its weight loss compound, Lepitrim(TM), to the Peoples Republic of China. |
| 03/20/06 | Imagenetix Commissions New Study to Evaluate Celadrin(R) Capsules for Patients with Knee Osteoarthritis
The primary purpose of this study is to confirm the positive clinical results, published in 2002 in the internationally acclaimed peer-reviewed Journal of Rheumatology... |
| 11/30/05 | Imagenetix
Announces Release of Celadrin/Glucosamine Combination Product The new Glucosamine/Celadrin® combination is expected to produce enhanced action of its two components... |
| 11/22/05 | Imagenetix
Second Quarter Revenue up 95 Percent Non-Cash Charge of $5.3 Million Related to Warrants and Options Results in Loss |
| 11/16/05 | Imagenetix
Licenses Patent Related to Body Fat Control Commercialization of Fat Reduction Product to Commence Immediately |
| 09/27/05 | Jeffrey
McGonegal Appointed to Imagenetix Board of Directors and Appointed
Chairman of the Audit Committee and Its Financial Expert Mr. McGonegal has unique in-depth expertise in merger and acquisition matters, in analyzing financial alternatives for growth oriented companies |
| 09/26/05 | Bob
Burg Appointed to Imagenetix Board of Directors Owner of The Burg Group, Mr. Burg's 25 years of business experience have focused on sales and marketing campaigns, channel distribution, and product sourcing. |
| 08/16/05 | Imagenetix
Reports Record Quarter Sales Hit All Time High - Up 142%. Before-Tax Income Soars 174%. Company Reports Ten Consecutive Quarters of Operating Profits |
| 07/20/05 | Imagenetix Reports Record Year Sales Jump 66% -- Net Income Increases 62%, and Company Reports Nine Consecutive Quarters of Profits |
| 05/03/05 | Jason
Theodosakis and Lorna Vanderhaeghe Join Imagenetix's Scientific and
Medical Advisory Board Bill Spencer, CEO of Imagenetix, said, "It gives me great pleasure to welcome Dr. Jason Theodosakis and Lorna Vanderhaeghe, two highly regarded authors and internationally acclaimed medical and health professionals to the Imagenetix Scientific and Medical Advisory Board." |
| 04/21/05 | Joining
the Imagenetix Scientific and Medical Advisory Board are Robert B.
Zurier, M.D., and William J. Kraemer, Ph.D Bill Spencer, CEO of Imagenetix said, “We are very pleased to welcome Robert Zurier, M.D., who is a highly respected researcher and an expert in rheumatoid arthritis... |
| 04/13/05 | Dr.
Reddy’s Launches Celadrin® as A Pharmaceutical Product
in India Celadrin has been approved for use as a pharmaceutical product in India to help reduce pain and inflammation in patients with joint conditions. |
| 04/07/05 | Imagenetix Announces Formation of Scientific and Medical Advisory Board Scientific and Medical Advisory Board that will lend guidance to the company's research and provide counsel related to product development |
| 02/22/05 | Imagenetix Reports Third Quarter Results For the third fiscal quarter ended December 31, 2004, the Company reported revenue of $2,739,743, a 157% increase |
| 11/23/04 | Sales and Earnings Increase at Imagenetix as Company Reports Seventh Consecutive Quarter of Profitability For the second fiscal quarter ended September 30, 2004, the company reported revenue of $1,034,146.00 |
| 08/23/04 | Earnings
Increase 280% at Imagenetix For the first fiscal quarter ended June 30, 2004, the company reported revenue of $1,186,163 |
| 07/19/04 | RFourth
Quarter Sales Increase 60% and Earnings Increase 460% as Imagenetix
Reports Record Fourth Quarter and Year End Results For the fourth fiscal quarter ended March 31, 2004, the company reported revenue of $1,645,199, a 60% increase |
| 04/01/04 | Researchers
Discover Arthritis Topical Cream Significantly Reduces Symptoms Imagenetix Announced the Publication of Its Clinical Study in The Journal of Rheumatology |
| 02/17/04 | Imagenetix
Reports 31% Increase in Quarterly Sales and Fourth Consecutive Quarter
of Profitability For the third fiscal quarter ended December 31, 2003, the company reported revenue of $1,066,399, an increase of 31% |
| 11/13/03 | Imagenetix
Congratulates Newport Bioceuticals On Successful Television Infomercial
Test-Airing of Zylogen Real Pain Relief The infomercial features Zylogen(TM) Real Pain Relief which provides penetrating pain relief for minor aches and pains of muscles and joints associated with arthritis, simple backache, strains, bruises, and sprains. |
| 07/14/03 | Imagenetix
Reports Fourth Quarter and Year End Results www.imagenetix.net, an innovator of scientifically tested, natural based, proprietary bioceutical products developed to enhance human and animal health on a global basis, today announced fiscal results for the fourth quarter and year ended March 31, 2003. |
| 05/30/03 | Cetylated
Fatty Acid Cream Improves Quality of Life, Functional Performance and
Range of Motion in Clinical Study A topical cream composed of cetylated fatty acids (CFA) can improve quality of life and mobility in patients with osteoarthritis |
| 04/28/03 | Imagenetix
Expands Marketing Efforts Initial test marketing of select private labeled products is scheduled to begin over the radio and through a television infomercial during the next 45 days. |
| 04/14/03 | Imagenetix
Presents Data From Clinical study on Cetylated Fatty Acids Absorption
and Metabolism at Experimental Biology 2003 Conference San Diego based Imagenetix, Inc. www.imagenetix.net (OTCBB: IAGX) announces promising research on the bioavailability of a proprietary Imagenetix compound was detailed in a poster presentation at the Experimental Biology 2003 Conference in San Diego on Saturday, April 12. |
| 04/02/03 | Imagenetix
Files Patent on Genepril™ Imagenetix is seeking claims for the prevention and treatment of various types of arthritis and other inflammatory joint diseases as well as psoriasis, lupus, and cardiovascular conditions. |